Table 4 Pattern of post-vaccine COVID-19 infection in group B (N = 70)
From: Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt
N = 70 | |
|---|---|
Frequency according to duration of infection | |
> 14 days of 1st dose | 19 (27.1%) |
> 28 days of 1st dose | 8 (11.4%) |
> 14 days of 2nd dose | 6 (8.6%) |
> 28 days of 2nd dose | 37 (52.9%) |
Duration from vaccine to infection (days) | 41 (14–303) |
Diagnostic swab for PCR | 22 (31.4%) |
Diagnostic chest HRCTa | 21 (30%) |
Diagnostic symptomsb | 69 (98.6%) |
Fever | 63 (90%) |
Headache | 53 (75.7%) |
Myalgia | 59 (84.3%) |
Ageusia | 18 (25.7%) |
Anosmia | 20 (28.6%) |
Cough | 52 (74.3%) |
Diarrhea | 7 (10%) |
Rhinorrhea | 21 (30%) |
Sore throat | 28 (40%) |
Dyspnea | 32 (45.7%) |